Short Communication | Published 21 February 2019
Petra Pokorná* and Jana Prausová
Department of Oncology, University Hospital in Motol, Charles University, V Uvalu 84, 150 00, Prague, Czech Republic
In recent years a significant progress is evident in the breast cancer treatment, which leads to the improvement of patients’ prognosis and to the prolongation of their overall survival. There are two new drugs, namely pertuzumab (in combination with trastuzumab and chemotherapy) and trastuzumab emtansine (TDM-1) a conjugate antibody and antineoplastic agent –which can be used in aselect group of patients with metastatic HER2 positive breast cancer. Experience gained from our clinical practice has confirmed both the safety of both chemicals and the gained profit for patients.
Keywords:
Advanced HER2 positive breast tumor, pertuzumab, trastuzumab emtansin, side effects
MESFORD Publisher Inc is a premier global publisher of science, technology and medical resources. We offer unique, trusted content by expert authors, spreading knowledge and promoting discovery worldwide. We aim to broaden thinking and advance understanding in the sciences, providing researchers, academics, professionals, and students with the tools they need to share ideas and realize their potential